Olatec Therapeutics

Olatec Therapeutics

Leading the Development of Specific NLRP3 Antagonists, Mediator of Innate Inflammatory Response

Founded 2003

New York, United States 15 employees Grant Total: $102.26M Biopharma, Biotechnology +2

Olatec Therapeutics is a privately held biopharmaceutical company founded in 2003 that is leading the development of specific NLRP3 antagonists, which are the mediators of the innate inflammatory response. The company is focused on developing a platform of safe, oral NLRP3 antagonist therapeutics to address a wide range of acute and chronic inflammatory diseases, including arthritis, heart failure, asthma, Alzheimer’s disease, multiple sclerosis, type-2 diabetes, melanoma, and breast cancers, among others. Olatec's lead compound, dapansutrile (lab code: OLT1177®), selectively targets NLRP3 to inhibit the production of pro-inflammatory cytokines IL 1B and IL 18, thus showing promise in treating these conditions. The company's last investment, a grant investment, was secured on 10 March 2023 from the Michael J. Fox Foundation. Olatec's drug development team, with over 10 years of experience, has unparalleled expertise in inflammation and immunology and includes international thought leaders. Olatec operates in the United States and Europe, with offices in New York and the Netherlands. With its innovative approach and focus on addressing unmet medical needs in the field of inflammatory diseases, Olatec Therapeutics has the potential to make a significant impact in the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries.

Funding Stage	Amount	Investors	Lead Investors	Date
Grant	Undisclosed	1	The Michael J. Fox Foundation for Parkinson's Research	10 Mar 2023
Series A	$40.00M	3	Advection Growth Capital, Milano Investment Partners +1	23 Feb 2023
Series A	$7.55M	-		01 Aug 2019
Series A	$15.00M	-		18 Oct 2018
Series A	$8.77M	-		29 Sep 2015
Series A	$15.00M	-		30 Aug 2013
Series A	$10.74M	-		26 Apr 2012
Series A	$2.16M	-		25 Feb 2011
Series A	$1.65M	-		10 Feb 2010
Series A	$1.39M	-		16 Apr 2008

Funding Stage

Amount

Investors

Lead Investors

Date

Grant

Undisclosed

The Michael J. Fox Foundation for Parkinson's Research

10 Mar 2023

Series A

$40.00M

Advection Growth Capital, Milano Investment Partners +1

23 Feb 2023

Series A

$7.55M

01 Aug 2019

Series A

$15.00M

18 Oct 2018

Series A

$8.77M

29 Sep 2015

Series A

$15.00M

30 Aug 2013

Series A

$10.74M

26 Apr 2012

Series A

$2.16M

25 Feb 2011

Series A

$1.65M

10 Feb 2010

Series A

$1.39M

16 Apr 2008

FAQ About Olatec Therapeutics

Leading the Development of Specific NLRP3 Antagonists, Mediator of Innate Inflammatory Response

Olatec Therapeutics was founded in 2003.

Olatec Therapeutics is headquartered in New York, United States.

Olatec Therapeutics operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on biopharmaceutical company, NLRP3 antagonist, IL-1 mediated diseases and inflammatory diseases.

Olatec Therapeutics has approximately 15 employees.

Olatec Therapeutics has completed 10 funding rounds, raising a total of $102.26M. The latest funding stage is Grant.

Top alternatives and competitors to Olatec Therapeutics include NodThera, Allakos Inc, InflaRx, X4 Pharmaceuticals, Third Harmonic Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Olatec Therapeutics and NodThera are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Olatec Therapeutics

Funding Rounds & Investors (10)

Olatec Therapeutics Alternatives & Competitors

FAQ About Olatec Therapeutics